Graham Lumsden, BVM&S, MRCVS

President, CEO, and Executive Director

Dr. Lumsden joined Biomarck as President and Chief Executive Officer in January 2021. He is a Non-Executive Director and the former CEO of Motif Bio where he raised $125 million, including two IPOs (AIM and NASDAQ), to advance iclaprim, a targeted antibacterial, through Phase 3 and NDA submission. Dr Lumsden previously founded and was the CEO of Tiemed LLC, a biotech company developing solutions for patients with difficulties taking oral medicines. Before that, Dr. Lumsden spent more than 10 years at Merck & Co., Inc., where he gained global experience in both the veterinary and human health markets, including worldwide businesses at Merck with annual revenues of more than $1 billion. Dr. Lumsden brings extensive domestic and international senior leadership experience in pharmaceuticals and biotechnology, including capital markets, corporate governance, new product launches, preclinical and clinical development, regulatory strategy, sales and marketing, business development, CMC and IP strategy. Dr. Lumsden received his Bachelor of Veterinary Medicine & Surgery from University of Edinburgh, U.K. and his Postgraduate Diploma in Marketing from the Chartered Institute of Marketing in the U.K.

LinkedIn

Alistair Wheeler, MB BS, MFPM

Chief Medical Officer

Dr. Wheeler joined Biomarck as Chief Medical Officer on a part-time basis in February 2021. Previously, he was Global Head of Clinical Development, Respiratory Medicine and Biotherapeutics at Sunovion Pharmaceuticals and prior to Sunovion, he was Senior Director of Clinical Research at Cubist Pharmaceuticals, Vice President of Medical Affairs at Avant Immunotherapeutics, Director, Respiratory Medicine at Astra USA and a clinical research physician for Glaxo Group Research. Dr. Wheeler brings decades of drug development know-how to the position, including leadership roles in nine successful filings of marketing applications with regulatory agencies worldwide. He has considerable experience in medical and regulatory affairs, with a particular focus on respiratory products and associated indications. At Biomarck, Dr. Wheeler is responsible for all medical and clinical aspects of development, with an initial focus on the clinical development program for BIO-11006 in acute respiratory distress syndrome (ARDS). Dr. Wheeler received his medical doctor degree from the Royal London Hospital Medical College, and his MFPM from the Royal College of Physicians. He is a member of the American Thoracic Society and a former vice president of the American Academy of Pharmaceutical Physicians.

Lawrence B. Florin, MBA

Clinical Operations Consultant

Mr. Florin joined Biomarck as Head of Clinical Operations in February 2021. Larry has extensive experience in global leadership roles overseeing clinical operations, project management, patient engagement, clinical technology, outsourcing and business development for sponsors, CRO, SMO and technology consulting organizations, managing programs across multiple therapeutic areas including pediatric and orphan disease indications and medical devices. He has held leadership positions most recently at Cognizant, Medidata, Ora, AstraZeneca and PRA. Mr. Florin received his BSc in Biology from Ursinus College, and his Executive MBA from Temple University. He has been an advisory board member at ACRP, RAPS, ACM and ARVO.

Chris Lehman, MBA

Chief Financial Officer / Advisor

Mr. Lehman joined Biomarck as interim CFO advisor in April 2021. He is a seasoned financial and business development leader in the life sciences industry with an exceptional combination of strategic partnering & financial leadership experience with venture-backed private and public industry leaders in therapeutics, diagnostics, CRO and industrial biotech. Since January 2021, he has acted as lead or co-lead IPO project manager for 4 biotech companies. Earlier, as CFO of a private immune-oncology company, Mr. Lehman drove and completed all IPO readiness efforts, forming a bulge bracket underwriting syndicate, leading 3 confidential S-1 filings, and establishing SOX compliant internal control and reporting processes. He has led or supported 40+ partnering and financing transactions totaling $600+ million and has made numerous presentations to potential investors and partners in the United States, Europe, and Asia. He founded and grew a successful business development strategy consultancy with 20+ client engagements and received his MBA from the University of California at Berkeley and his BA from Yale University.

Rajin Ahuja

Executive Chairman of the Board

Mr. Ahuja possesses over 15 years of global experience in pharmaceutical mergers and acquisitions, and has an extensive background in drug development and co-development partnerships. Mr. Ahuja founded and launched his first pharmaceutical company in his mid-twenties, which successfully achieved FDA approval on three first-to-market drugs. He has had direct involvement in the interaction, negotiation, and licensing of many drugs with some of the most preeminent global pharmaceutical companies. His experience as an entrepreneur has led to the successful creation of several startup pharmaceutical companies that resulted in multimillion dollar valuations. In these ventures, Mr. Ahuja has been involved in raising the necessary capital to develop and commercialize products, and his expertise and experience have been instrumental in extracting top value for development funds. Recently, he has globalized his pharmaceutical reach into India, Russia, Canada, and South America. Mr. Ahuja is also a managing partner for an investment firm that administers medically related investments. He currently holds several board seats and provides strategic advice for many startups and medical companies.

Andrew Davis

Vice Chairman

Mr. Davis is currently an independent director at Biomarck. He has significant experience across the Business Development and Merger’s and Acquisitions landscape, having led over 70 transactions in his career. Mr. Davis has served as the Chief BD/M&A Officer at iNova Pharmaceuticals since September of 2017, leading all company transactions along with serving as a member of the company’s executive team. Additionally, Mr. Davis currently serves on the board of directors for Utility Therapeutics. Prior to iNova Mr. Davis served as the Head of Oncology Business Development at Merck since December 2016. Prior to Merck, Mr. Davis served as the SVP of Business Development of Valeant Pharmaceuticals (now Bausch Health Companies) a global pharmaceutical, consumer products and medical device company, leading all transactions for the company from 2014 to December 2016. Prior this this role Mr. Davis had increasing roles of responsibility within the Business Development function at Valeant, joining the company in 2012. Prior to Valeant, he served as a management consultant at McKinsey & Co. focused on the healthcare space from 2007-2012. Mr. Davis received his B.A. in Economics from Boston University in Boston Massachusetts.

Walker A. Long, MD

Director

Dr. Long is a physician, scientist, and medical researcher who develops new drugs. He joined the board of biomark Pharmaceuticals in 2004; he served as chairman from 2011 to 2014 and as CEO from 2013 to 2014. Dr. Long has worked in academia, large pharma, small pharma, and biotechnology companies. Dr. Long’s most recent position (2008-2012) was chief medical officer and vice president of drug development at Biolex Therapeutics, where he had responsibility for preclinical and clinical development and later regulatory affairs. Prior to that he was vice president of clinical development at AtheroGenics Inc. (2005-2008), where he was responsible for clinical development and statistics and later regulatory affairs. From 1999 to 2005, he was senior vice president at Cato Research, where he was the senior medical and scientific officer for more than 100 projects. From 1993 to 1998, he was on the full-time faculty of the UNC School of Medicine, where he earned tenure. From 1983 to 1993, he held positions of increasing responsibility in clinical development at Burroughs Wellcome Co., and served on the part-time faculty of the UNC School of Medicine. Dr. Long has 217 publications including 71 peer-reviewed articles, six patents, and more than 100 invited national and international presentations at scientific and medical meetings. Dr. Long’s accomplishments include the approvals of three first-in-class new chemical entities at three different FDA divisions. His research has resulted in a number of national and international awards including the Gold Pill Award and the Prix Galien.

Ashish C. Bhatia, MD

Director

Dr. Bhatia has extensive experience in drug development as well as medical and device research across multiple therapeutic areas. He has served on the advisory boards or the board of directors of private and public pharmaceutical companies across the globe. His background in both medicine and business is a unique asset for boards on which he serves. Dr. Bhatia is a founding member of a mid-capital investment firm and manages a portfolio of healthcare device and pharmaceutical companies in the U.S. and in Asia. He has served as principle investigator on Phase II, III and IV clinical studies across multiple disciplines. He also serves as a business development advisor to a number of public and private pharmaceutical companies. Dr. Bhatia founded and directed the Department of Clinical Research for a 700+ physician-directed medical group which performed clinical trials in over 17 specialties and contributed to bringing over 20 devices and drugs to market. He also co-founded the group’s Charitable Fund which contributed over $5 million per year in program support and in-kind services related to food, shelter and healthcare to the communities served by the group.

Amit Shah

Director

Mr. Shah is a successful entrepreneur in the Pharmaceutical development and finished dosage arena. He successfully transformed Bio-Pharm Inc. from a small over the counter medicine manufacturer to a research and development / manufacturer of specialty prescription pharmaceutical products. Amit has developed and licensed products to several of the top pharmaceutical companies in the world. His knowledge of product development vastly covers all dosage forms. He is a strong believer in the network, and that working with the right team will lead to success. Amit most recently lead corporate strategy at Bio-Pharm until the acquisition of Bio-Pharm by Torrent Pharmaceuticals, Inc. Torrent is a top 10 pharmaceutical company from India. Amit currently serves as the VP, Portfolio for Torrent Pharma, Inc. leading integration, business development and R&D.

Laura Calamos, PhD

Director

Laura Calamos, PhD, is a distinguished lecturer and researcher recognized internationally for teaching advanced assessment, clinical reasoning, research and leadership. She has been on faculty at the University of North Carolina at Chapel Hill since 2003, where she has had extensive experience working with clinicians and leaders across the globe. She has been an advanced practice registered nurse in both the UK and US with more than 20 years of direct patient care experience in primary care and public health, providing care in a variety of hospital and community settings including PBMT/oncology, sexual health, immunization, and family practice. Her background in client-centered service, quality improvement and management is also utilized in her role as Chief Administrative Officer of Calamos Family Partners, where she provides leadership for the firm’s cross-functional collaboration and strategic initiatives across multiple organizational entities. Additionally, Dr. Calamos continues to see patients in primary care as a board certified Family Nurse Practitioner. Dr. Calamos earned her Ph.D. from King’s College London in the UK, completing nationally funded research in the social sciences by examining the integration of services across the health care system.

Thomas H. Roberg

Board Observer, Co-Founder

Mr. Roberg, co-founder of Biomarck, is a 44-year veteran of the information technology (IT) industry, where he was principally involved in general management, marketing, and sales. Mr. Roberg was elected Chairman of the Wake County Republican Party in 1993; in 1998, he was a candidate for United States Congress, where he was narrowly defeated. For the last 15 years, he has been heavily involved in venture capital markets as an investor, consultant, and board member. He is an active member of the Research Triangle community and serves on many boards and foundations. His current board positions include BioMedomics and Panacea. Named chairman of the North Carolina Business Council on the Arts, he is a leading figure in North Carolina politics, arts, and the business community.